Drug Name |
Cefadroxil |
Drug ID |
BADD_D00379 |
Description |
Long-acting, broad-spectrum, water-soluble, cephalexin derivative. |
Indications and Usage |
For the treatment of the following infections (skin, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphylococci and Streptococcus pyogenes |
Marketing Status |
Prescription; Discontinued |
ATC Code |
J01DB05 |
DrugBank ID |
DB01140
|
KEGG ID |
D00257
|
MeSH ID |
D002434
|
PubChem ID |
47965
|
TTD Drug ID |
D0X9ZC
|
NDC Product Code |
65862-083; 63187-883; 0143-9767; 67296-1038; 57237-098; 16714-388; 45865-503; 16714-389; 63629-7615; 43063-553; 72189-103; 65862-359; 68071-4690; 68788-7484; 0143-9948; 68071-4938; 43063-595; 70934-056; 0143-9947; 57237-097; 67296-1727; 70934-081; 65862-084; 68180-182; 68180-181; 68180-180; 57237-096; 68071-5234; 65862-085; 0143-9766; 53002-2290; 50090-0580; 16714-390; 55289-589; 50090-1915; 0093-3196; 68071-4515; 0093-4059; 66267-045; 70518-2538 |
Synonyms |
Cefadroxil | Cephadroxyl | Cefadroxil Anhydrous | 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- | Ultracef | Bidocef | Duricef | BL-S 578 | BL S 578 | BLS 578 | BL-S578 | BL S578 | BLS578 | S-578 | S 578 | S578 | 4-Hydroxycephalexin | 4 Hydroxycephalexin | Cefadroxil Monohydrate |